

[Skip to main content](#)

# Karbinal ER (Carbinoxamine Maleate Extended-Release Oral Suspension)

Zuletzt aktualisiert: 30. November 2017

**].WARNINGS AND PRECAUTIONS** Use of Karbinal ER may result in decreased mental alertness with impaired mental or physical abilities [see

The most frequent adverse reactions include: sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, and thickening of bronchial secretions. In  
].**Geriatric Use** and **Pediatric Use**clinical use, younger children and older adults may be particularly sensitive to adverse reactions [see

The following adverse reactions, listed by body system, have been identified in case reports and during the use of carbinoxamine in observational studies. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat. **Body as a Whole:**

Hypotension, headache, palpitations, tachycardia, extrasystoles. **Cardiovascular:**

Fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, **Central Nervous System:**  
vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.

Anorexia, nausea, vomiting, diarrhea, constipation. **Gastrointestinal:**

Hemolytic anemia, thrombocytopenia, agranulocytosis. **Hematologic:**

Increase in uric acid levels. **Laboratory:**

Tightness of chest and wheezing, nasal stuffiness. **Respiratory:**

Urinary frequency, difficult urination, urinary retention, early menses. **Urogenital:**